含整合酶抑制剂方案抗HIV治疗临床疗效和安全性评价  

Evaluation of the clinical efficacy and safety of anti-HIV treatment with integrase inhibitor-containing schemes

作　　者：李丽丹 董文逸[2] 韦玉素 黄金萍[2] 黎彦君[2] 梁冰玉[1] 林健燕 LI Lidan;DONG Wenyi;WEI Yusu;HUANG Jinping;LI Yanjun;LIANG Bingyu;LIN Jianyan(School of Public Health,Guangxi Medical University,Nanning,Guangxi Zhuang Autonomous Region 530022,China)

机构地区：[1]广西医科大学公共卫生学院,广西壮族自治区南宁530022 [2]南宁市第四人民医院 [3]南宁市第一人民医院

出　　处：《医学动物防制》2024年第11期1108-1113,共6页Journal of Medical Pest Control

基　　金：广西自然科学基金面上项目(2018GXNSFAA138070)。

摘　　要：联合抗逆转录疗法(combined antiretroviral therapy, cART)可以最大限度的抑制HIV复制,但随时间延长,耐药性、药物不良反应、患者服药的依从性等问题逐渐突显。药物不良反应是抗逆转录病毒治疗(antiretroviral treatment, ART)中断的主要原因,影响治疗疗效。简化治疗可以在持续抑制病毒复制的同时减少药物不良反应。单片复方制剂(single pill combination, SPC)是含几种不同成分的抗逆转录病毒药物,分别作用于HIV复制的不同环节,是临床上简化治疗的新策略。整合酶抑制剂(integrase inhibitors, INIs)相较于传统的ART药物有能快速降低HIV RNA浓度、耐药屏障高、不良反应小等优点。本文对整合酶抑制剂的SPC的疗效和安全性进行综述,以提高医护人员和患者对此类药物的认识。Combined antiretroviral therapy(cART)can maximize the inhibition of HIV replication,but with the prolongation of time,drug resistance,adverse drug reactions,drug compliance of patients and other issues become increasingly prominent.Adverse drug reactions are the main reason for the interruption of antiretroviral treatment(ART)and affect the therapeutic efficacy.Simplified treatment can reduce adverse drug reactions while continuing to suppress viral replication.Single pill combination(SPC)is an antiretroviral drug containing several different components acting on different links of HIV replication,which is a new strategy to simplify treatment in clinical practice.Compared with traditional ART drugs,integrase inhibitors have the advantages of rapidly reducing HIV RNA concentration,high drug resistance barrier,and small adverse reactions.This article reviews the efficacy and safety of SPC of Integrase inhibitors to improve the understanding of medical staff and patients on this kind of drugs.

关 键 词：整合酶抑制剂 单片复方制剂 抗逆转录病毒治疗 药物不良反应 疗效 安全性 

分 类 号：R512.91[医药卫生—内科学]